Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy + PD-1 inhibitor + anlotinib versus chemoradiotherapy + PD-1 inhibitor in locally advanced non-small cell lung cancer
ChiCTR2400081602Phase 2Not yet recruiting
- Sponsor
- Department of Oncology, Affiliated Hospital of Southwest Medical University
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of anlotinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Department of Oncology, Affiliated Hospital of Southwest Medical University. Primary endpoint: One-year progression-free survival rate. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
anlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2400081602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400081602.